In a significant step toward strengthening India’s pharmaceutical self-reliance and sustainable manufacturing ecosystem, the Technology Development Board (TDB) under the Department of Science and Technology (DST), Government of India, has extended financial support to Chennai-based Bioneemtec India Private Limited. The support is aimed at facilitating the commercialization of advanced indigenous technologies for manufacturing critical pharmaceutical ingredients, intermediates, and innovative drug delivery systems.
The project, titled “Manufacturing of Minoxidil, Tranexamic Acid, Dequalinium Chloride, their Intermediates and Drug Liposomes,” is designed to enhance domestic production capabilities while reducing dependence on imported pharmaceutical raw materials. The initiative aligns with India’s broader objective of strengthening healthcare security and promoting environmentally responsible industrial practices.
Under the project, Bioneemtec plans to establish advanced manufacturing infrastructure for Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and next-generation drug delivery platforms. The company will employ a combination of batch processing and continuous-flow chemistry technologies to improve production efficiency, ensure product consistency, and enhance operational safety. These modern manufacturing approaches are also expected to reduce waste generation and lower the environmental footprint of pharmaceutical production.
A major focus of the initiative is the commercialization of an indigenous technology for producing Tranexamic Acid, a widely used therapeutic compound for managing bleeding disorders. The process has been developed using a cost-effective and eco-friendly synthesis route that enables the production of high-purity material while minimizing process complexity and industrial waste. The successful commercialization of this technology is expected to strengthen domestic availability of the drug and reduce reliance on imported supplies.
In addition to Tranexamic Acid, the project will support local production of Minoxidil and Dequalinium Chloride, along with their key intermediates. These pharmaceutical compounds are extensively used in various therapeutic applications and currently rely significantly on imported raw materials and manufacturing inputs. Expanding domestic manufacturing capacity in these segments is expected to reinforce India’s pharmaceutical supply chain and improve resilience against global disruptions.
The project also incorporates an advanced innovation component through the development of proprietary Drug Liposome APIs. Leveraging nanotechnology-based platforms, Bioneemtec has developed liposomal formulations intended for therapeutic applications, including breast cancer and skin cancer treatment. According to the company, the formulations have demonstrated promising results with controlled nanoparticle characteristics, which are essential for targeted and efficient drug delivery.
To safeguard its innovations, the company has initiated intellectual property protection measures for its liposomal technology. The move is expected to create opportunities for future development of advanced therapeutic solutions and strengthen India’s position in the high-value pharmaceutical innovation segment.
Speaking on the occasion, Rajesh Kumar Pathak, Secretary, Technology Development Board, emphasized the growing importance of sustainable and technology-driven pharmaceutical manufacturing. He noted that the future of the sector depends on production systems that combine efficiency, quality, and environmental responsibility. He further highlighted that indigenous development of advanced APIs, pharmaceutical intermediates, and innovative drug delivery technologies will play a crucial role in reinforcing India’s status as a global pharmaceutical manufacturing hub.
Pathak reiterated TDB‘s commitment to supporting enterprises that develop high-value technologies capable of reducing import dependence while contributing to national healthcare preparedness and industrial competitiveness.
Expressing appreciation for the support, the leadership of Bioneemtec India Private Limited stated that the project would significantly accelerate the commercialization of the company’s green chemistry-based manufacturing processes and advanced pharmaceutical products. The support is expected to help scale production capabilities, strengthen indigenous API manufacturing, and expand the development of next-generation therapeutic formulations.
As India continues to emerge as a global center for pharmaceutical production and innovation, initiatives such as this are expected to contribute substantially to technological advancement, sustainable manufacturing practices, and long-term healthcare security while opening new opportunities in both domestic and international markets.
Also Read: Indian Developer Shines as Apple Announces Winners of 2026 Design Awards
Author: Shivam
Shivam Dwivedi is a senior journalist with extensive experience in research-driven journalism, policy communication, and multi-platform storytelling. His areas of interest include international relations, defence, science & technology, education, urban development, agriculture, spirituality, and environmental sustainability. His work focuses on in-depth analysis, public discourse, and impactful narratives across governance and development sectors, with a strong commitment to the Sustainable Development Goals (SDGs). Contact: [email protected]
